With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9
To a solution of 6-bromoquinoxaline (500 mg, 2.39 mmol, 1 eq.) in 1,4-dioxane (10 mL) was added 5-(4,4,5,5-Bis(pinacolato)diboron (729 mg, 2.87 mmol, 1.2 eq.), KOAc (469 mg, 4.78 mmol, 2 eq.), and PdCl2dppf?DCM complex (195 mg, 0.23 mmol, 0.1 eq.). The reaction mixture was deoxygenated with N2 allowed stir at 80 C. for 18 h. The reaction mixture was cooled to RT, diluted with water (50 mL) and extracted with ethyl acetate (2*50 mL). Combined organic layer was washed with brine (20 mL) and dried over sodium sulfate. Removal of solvent under reduced pressure gave crude which was purified by normal phase Combi-flash column chromatography (0-100% EtOAC-Hexane) to afford quinoxalin-6-ylboronic acid (350 mg, 85%) as brown oil.
The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; GiraFpharma LLC; PHAM, Son Minh; CHEN, Jiyun; ANSARI, Amantullah; JADHAVAR, Pradeep S.; PATIL, Varshavekumar S.; KHAN, Farha; RAMACHANDRAN, Sreekanth A.; AGARWAL, Anil Kumar; CHAKRAVARTY, Sarvajit; (120 pag.)US2019/23666; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider